Overview

A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse

Status:
Active, not recruiting

Trial end date:
2020-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the clinical benefit and safety of two different Dose-Intense temozolomide regimens（one-week on/one-week off regimen versus continuous dose-intense regimen）in patients with glioblastoma at first relapse.

Phase:

Phase 2

Details

Lead Sponsor:

Beijing Sanbo Brain Hospital

Treatments:

Dacarbazine
Temozolomide